Abstract-Identification of biomarkers and/or mediators of cardiovascular disease (CVD) associated with HIV infection would be of diagnostic and therapeutic value. As soluble receptor for advanced glycation endproducts (sRAGE) and endogenous secretory (esRAGE) have been implicated in vascular complications in other settings, we investigated whether either soluble form of RAGE was associated with changes in carotid intima-media thickness (CIMT) in HIV-infected patients and HIV-uninfected controls. We found no differences in sRAGE, esRAGE, or CIMT among groups at study entry, or in yearly rates of change in sRAGE, esRAGE, or CIMT by HIV-serostatus (all p > 0.10). However, yearly rates of change in sRAGE (p = 0.07) and esRAGE (p < 0.001) were higher in those taking protease inhibitors, and lower baseline esRAGE levels (p = 0.06) were associated with increased odds of CIMT progression in HIV-infected individuals. Although esRAGE was not altered by HIV-serostatus (p = 0.17), its inverse relationship with CIMT progression in HIVinfected patients suggests a possible role as a mediator of CVD in HIV-infected persons.
INTRODUCTION
Following institution of antiretroviral therapy, cardiovascular disease (CVD) has become a major cause of morbidity and mortality in HIV-infected individuals [1, 2] , and the cardiovascular risk appears greater than that predicted by conventional risk factors [1] [2] [3] [4] [5] [6] [7] [8] [9] . Although a number of biomarkers have been investigated [10] [11] [12] [13] [14] [15] , including serum biomarkers of microbial translocation (LPS) and macrophage activation (sCD14) by our group [16] , identification of additional markers and/or mediators contributing to excess cardiovascular risk would be of great value. The receptor for advanced glycation endproducts (RAGE) is one potential candidate. RAGE has been implicated in the pathogenesis and progression of chronic diseases such as diabetes, atherosclerosis, and other immune/ inflammatory disorders (such as rheumatoid arthritis and sepsis) [17] . RAGE is a member of the immunoglobulin Summary of Major Findings: This work suggests a possible role for sRAGE and/or esRAGE as mediators of cardiovascular disease in HIV-infected persons.
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superfamily of cell surface molecules, is expressed on multiple cell types (such as endothelial cells, smooth muscle cells, neutrophils, monocytes/macrophages, dendritic cells, T lymphocytes, and B lymphocytes), and binds to and transduces the signal stimulated by a number of ligands [including advanced glycation endproducts, proinflammatory S100/calgranulins, high-mobility group box-1 protein (HMGB1), and amyloid-beta peptide]. In humans, two soluble forms of RAGE are detectable, including soluble [sRAGE, a form of the extracellular receptor cleaved from the cell surface via the actions of various proteases such as a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and matrix metalloproteinases (MMPs)] and endogenous secretory (esR-AGE, the translation product of a splice variant of RAGE) [17] . In animals with atherosclerosis, diabetes, immune/ inflammatory activation, or chronic degenerative disorders, antagonism and/or genetic deletion of RAGE is remarkably protective in attenuating cellular stress and tissue damage [18, 19] . Numerous studies suggest that circulating levels of soluble RAGEs may serve as biomarkers or mediators of disease activity in humans as well [17, 20] . However, in humans, the relationship between RAGE and a variety of adverse outcomes may be more complex than that observed in animal models. Piarulli and colleagues [21] have suggested that, in the setting of cardiovascular complications associated with diabetes in humans, sRAGE levels may change over time with disease activity. They propose that sRAGE levels are high in the early stages of inflammation; levels gradually decline in the intermediate stages (perhaps due to sequestration) and may rise again in the late stages of disease (as a result of increased cleavage and release of cell surface RAGE resulting from inflammation associated with acute cardiovascular events). Additional studies aimed at clarifying the relationship between sRAGE and esRAGE in each stage of disease are essential to identify the mechanistic links between levels of sRAGEs and chronic diseases such as HIV, diabetes, and cardiovascular disease. Interestingly, in some studies, therapeutic interventions with statins, angiotensin converting enzyme (ACE) inhibitors, or calcitrol-modulated sRAGE levels, treatment with these therapeutic agents resulted in higher levels of sRAGE compared to the pretreatment values [22] [23] [24] .
Little is known about whether sRAGE or esRAGE is modulated by HIV infection or its treatments, especially PI therapy, which has been implicated in HIV-associated CVD [1] [2] [3] [4] [5] [6] . Therefore, we utilized stored samples from the previously reported prospective, matched cohort ACTG A5078 study [25] originally designed to study the role of PI therapy and HIV infection on the risk of development of subclinical atherosclerosis and its progression (as evaluated by progression of carotid intima-media thickness, CIMT) to investigate whether there are associations between HIV infection, PI exposure, CIMT, and the novel inflammatory biomarkers/mediators sRAGE and esRAGE. In accordance with the suggestion of Piarulli and colleagues [21] postulating triphasic levels of sRAGE and esRAGE, we hypothesized that sRAGE and esRAGE levels would be intermediate at baseline in this cohort selected for low cardiovascular risk, but with chronic underlying inflammation resulting from HIV infection and would increase over time in association with CIMT progression.
MATERIALS AND METHODS

Study Design
This study is a secondary analysis of the previously reported [25] clinical trial A5078: BProgression of carotid artery intima-media thickening in HIV-infected anduninfected adults: a pilot study.^Briefly, A5078 was a prospective, matched cohort study designed to investigate the role of PI therapy and HIV infection on the risk of development of subclinical atherosclerosis and its progression, which enrolled 134 individuals into 45 triads (each comprised of three individuals matched for six cardiovascular risk factors including age, sex, race/ethnicity, smoking status, blood pressure, and menopause status) from eight university-based outpatient HIV clinics. Each triad consisted of one individual from each of the following groups: group 1, HIV-infected individuals with continuous use of PI therapy for ≥2 years (n = 44, HIV/PI); group 2, HIV-infected individuals without prior PI use (<3 cumulative months PI therapy permitted, n = 44, HIV/not PI); and group 3, HIV-uninfected individuals (n = 44, not HIV). Baseline and longitudinal measurements, including CIMT, were obtained at weeks 0, 24, 48, 72, 96, and 144. Individuals were excluded if they had diabetes mellitus, family history of early myocardial infarction in first-degree relatives, a history of coronary heart disease or stroke, uncontrolled hypertension, untreated hypothyroidism, or obesity. Individuals requiring systemic chemotherapy, radiation therapy, or systemic steroids were also excluded, as were individuals with a serum creatinine >1.5 mg/dL or alanine or aspartate aminotransferases >2.5× upper limit of normal.
In this secondary analysis utilizing stored A5078 samples, levels of plasma sRAGE and esRAGE were measured at weeks 0, 72, and 144 in individuals who also had HIV RNA <500 copies/mL and CIMT results at all time points (in the cases where a week 144 sample was not available, a week 96 sample was utilized, thus referred to as Bweek 96/144^). The 80 participants who had the required RNA level and sufficient residual sample to be included in this analysis were from 40 triads (group 1: n = 25; group 2: n = 21; and group 3: n = 34), of which 9 triads were complete. The A5078 informed consent document included the provision for future testing of stored samples for ACTGapproved AIDS-related research.
Data Collection
Fasting glucose, insulin, lipids, cardiovascular/ metabolic disease-related measurements (including homocysteine and high-sensitivity C-reactive protein (hs-CRP)), CD4+ cell counts, and HIV-1 RNA levels were collected at A5078 study entry. The CIMT at the far wall of the right distal common carotid artery was measured at baseline and longitudinally [25] . In this study, plasma sRAGE and esRAGE levels were assayed on stored samples using enzyme-linked immunosorbent assay (ELISA) kits in accordance with the manufacturer's protocol (R&D Systems Quantikine Immunoassay Minneapolis, MN, and B-Bridge ELISA, B-Bridge International, Cupertino, CA, respectively). Serum sCD14 and LPS were measured on stored samples as previously published [16] .
Statistical Methods
In this small, exploratory secondary analysis, results with two-sided p values <0.10 were deemed a priori as worthy of future investigation; no adjustments were made for multiple comparisons. By-group comparisons of baseline characteristics and biomarkers were assessed using the Fisher's exact, Wilcoxon, and Kruskal-Wallis tests as appropriate. The yearly rate of change in each biomarker was based on three time points for each participant. Using a 48-week year, simple linear regression was used to calculate each participant's yearly rate of change (i.e., slope) in the biomarker (reported in biomarker unit/year). A matched analysis comparing the HIV/PI and HIV/not PI groups (11 matched pairs) assessed the effect of PI therapy on RAGE in the HIV-infected participants using a Wilcoxon test. The comparison of the HIV/not PI and not HIV groups (17 matched pairs; or the combined HIV group against the not HIV group if there was no PI effect; 29 matched pairs/ triplets) assessed the effect of HIV infection on RAGE. A variation on the Wilcoxon signed-rank test was used to compare up to two HIV-infected participants with one HIV-uninfected participant [26] . Mixed models regression analyses with triad as a random effect evaluated whether baseline measurements of sRAGE and esRAGE were associated with other baseline variables. Repeated measures regression analyses with triad as a random effect evaluated associations with yearly rates of change in sRAGE, esR-AGE, and CIMT. Progression of CIMT was defined in A5078 as yearly rate of change ≥12.2 μm/year. Conditional logistic regression modeling for matched pairs data stratified by triad evaluated associations of baseline variables with the odds of CIMT progression. Variables with p < 0.20 in the univariable analysis were examined together in multivariable analysis and reduced using the backward elimination method, with the final multivariable model containing variables with p < 0.10. The final multivariable models were adjusted for fasting glucose, statin use, total cholesterol ≥200 mg/dL, non-HDL cholesterol, and BMI. Regression models were also fit in the HIV-infected and HIV-uninfected subgroups. SAS version 9.2 was used for the statistical analysis.
RESULTS
Baseline Characteristics
Participant characteristics are summarized in Table 1 . The participants were 91 % male, 75 % white/non-Hispanic, and 19 % Hispanic, with a median age of 41 years. The median baseline CIMT was 695 μm; there were no differences among the three study groups (p = 0.74). The 80 participants in this analysis were similar to the 54 who were excluded, except for race (p = 0.051; all five Black participants were excluded) and baseline triglycerides (p = 0.036; more participants with triglycerides ≥150 mg/ dL were excluded).
Comparisons of sRAGE and esRAGE at Weeks 0, 72, and 96/144 Among Study Groups
There were no differences in sRAGE or esRAGE levels among the three study groups at weeks 0, 72, and 96/144 (all p > 0.6; Table 2 ).
Effect of HIV Serostatus and PI Use on Yearly Rate of Change in sRAGE
There were positive yearly rates of change in sRAGE within the HIV/PI and combined HIV groups (median = 35 pg/mL/year, p = 0.07; and 34 pg/mL/year, p = 0.05, respectively; Table 2), with no changes over time within the HIV/not PI and not HIV groups (p = 0.25 and 0.14, respectively). In a matched analysis, there was no effect of HIV disease on the yearly rate of change in sRAGE (p = 0.60). PI use was associated with a modest increase in yearly rate of change in sRAGE (median of paired differences = 52 pg/mL/year; p = 0.08).
Effect of HIV Serostatus and PI Use on Yearly Rate of Change in esRAGE
In contrast to sRAGE, there were positive yearly rates of change in esRAGE within each study group (p < 0.001, p = 0.004, p < 0.001, respectively; Table 2 ) and within the combined HIV group (p < 0.001). Thus, week 96/144 esR-AGE was greater than week 0 esRAGE. The median yearly rates of change in esRAGE in the HIV/PI, HIV/not PI, and not HIV groups were 57, 41, and 43 pg/mL/year, respectively, and 44 pg/mL/year in the combined HIV group.
Similar to the matched analysis of sRAGE, there was no effect on the yearly rate of change in esRAGE associated with HIV disease (p = 0.17). A positive yearly rate of change in esRAGE was observed in those taking PIs (median of paired differences = 66 pg/mL/year; p = 0.08).
Relationship Between sRAGE and esRAGE
In univariable regression analysis in all participants, higher baseline sRAGE was associated with higher baseline esRAGE (p <0.001); this was also observed in the HIVinfected and HIV-uninfected participants (both p < 0.001) (Supplemental Table 2A ). A positive yearly rate of change Except otherwise indicated, data represent N (%) of participants a Because of missing data, the sample sizes were n = 79, n = 24, n = 21, and n = 34, respectively b Because of missing data, the sample sizes were n = 78, n = 23, n = 21, and n = 34, respectively c Because of missing data, the sample sizes were n = 74, n = 23, n = 20, and n = 31, respectively d Because of missing data, the sample sizes were n = 45, n = 24, and n = 21, respectively e Kruskal-Wallis test for between group differences in baseline CIMT (p = 0.74)
in esRAGE was associated with higher baseline sRAGE in all participants (p = 0.002) and in HIV-infected participants (p = 0.068) in univariable analysis (Supplemental Table 2B ).
Relationship Between sRAGE, esRAGE, and Baseline Variables
The adjusted multivariable regression analyses of baseline sRAGE and esRAGE are summarized in all participants and HIV-infected and HIV-uninfected participants in Table 3 . In the adjusted multivariable analysis in all participants (Table 3 ), higher baseline sRAGE was associated with lower baseline CIMT (p = 0.003), higher baseline esRAGE (p < 0.001), and higher BMI (p = 0.093). In the adjusted multivariable analysis in HIV-infected participants, only higher baseline esRAGE (p = 0.006) remained associated with baseline sRAGE. In the adjusted multivariable analysis in HIV-uninfected participants, higher baseline sRAGE was associated with higher baseline esRAGE (p < 0.001) and non-white race (p = 0.038).
In the adjusted multivariable analysis in all participants (Table 3 ), higher baseline esRAGE was associated with higher baseline sRAGE (p < 0.001 and lower BMI (p = 0.028). In the adjusted multivariable analyses in HIVinfected and HIV-uninfected participants, only higher baseline sRAGE remained associated with baseline esRAGE (p < 0.001 and p < 0.001, respectively).
A positive yearly rate of change in esRAGE was associated with lower baseline CIMT (p < 0.001), HDL ≥35 mg/dL (p = 0.007), higher non-HDL cholesterol (p = 0.035), and higher homocysteine (p = 0.047) in the adjusted multivariable analysis in all participants (Table 3 ). In the adjusted multivariable analysis in HIV-infected participants, HDL ≥35 mg/dL (p = 0.055), higher waist-to-hip The reference group used for determination of the parameter estimate was clarified as needed. In univariable analysis, the baseline variables considered for all participants were age, sex, race, HIV status, body mass index (BMI), waist circumference, waist/hip ratio, fasting lipid measurements [glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and insulin], use of lipid lowering drugs, use of statins, inflammatory measurements [high-sensitivity C-reactive protein (hs-CRP) and homocysteine], sCD14, LPS, sRAGE, esRAGE, and CIMT. p < 0.2 for all variables in univariable analyses were used to create a full multivariable model. The final multivariable models were adjusted for fasting glucose, use of statins, total cholesterol ≥200 mg/dL, non-HDL cholesterol, and BM a The multivariable models for yearly rate of change in esRAGE included 74, 43, and 31 participants, respectively, with complete data ratio (p = 0.089), and higher insulin (p = 0.036) remained associated with a positive yearly rate of change in esRAGE.
In HIV-uninfected participants, in the adjusted multivariable analysis, a positive yearly rate of change in esRAGE was associated with lower baseline CIMT (p = 0.036), triglycerides <150 mg/dL (p = 0.052), and higher hs-CRP (p = 0.065).
Progression of CIMT and Yearly Rate of Change of CIMT
In this secondary analysis of A5078, progression of CIMT was present in 38 % of participants, with a difference among the three groups (p = 0.08): 52 % in the HIV/PI group, 19 % in the HIV/not PI group, and 38 % in the HIVuninfected group (Table 2 ). In the HIV-infected participants (Table 3) , the adjusted multivariable analysis showed that increased odds of CIMT progression was associated with higher sCD14 (p = 0.043), HDL ≥35 mg/dL (p = 0.056), and lower esRAGE (p = 0.061). In the HIVuninfected participants, increased odds of CIMT progression was associated with only non-white race (p = 0.078).
There was no multivariable model for all participants.
Yearly Rate of Change in CIMT
In this analysis, there were no effects of HIV disease (p = 0.87) or PI use (p = 0.12) on the yearly rates of change in CIMT in a matched analysis (Table 2 ). There were positive yearly rates of change in CIMT within the HIV/ PI and not HIV groups (both p < 0.001) and within the combined HIV group (p = 0.002). The median yearly rate of change in CIMT in the HIV/PI, HIV/not PI, and not HIV groups was 13, 6, and 9 μm/year, respectively, and 8 μm/ year in the combined HIV group.
DISCUSSION
This is the first longitudinal study investigating a role for sRAGE or esRAGE as biomarkers and/or mediators of CVD in HIV-infected and HIV-uninfected individuals. Although glycation differences have been suggested in HIVinfected compared to HIV-uninfected individuals [27] [28] [29] , in this small subgroup of 80 A5078 study subjects, we did not find evidence that plasma levels of either form of sRAGE studied here were modulated by HIV status. However, we did find progression of CIMT associated with lower baseline esRAGE levels among those with HIV infection, which is consistent with a previous report in HIV-uninfected, diabetic individuals [30] . An inverse relationship between CIMT and sRAGE has also been demonstrated in HIV-uninfected nondiabetic [31] and diabetic [32] persons. In a prospective longitudinal study of Japanese subjects with type 1 diabetes, the investigators also noted an inverse correlation between CIMT and sRAGE and esRAGE, independent of traditional risk factors [33] . While no differences by HIV status in the yearly rates of change in sRAGE or esRAGE were found, the yearly rates of change in sRAGE and esRAGE were higher among those taking PIs. In the context of previous studies showing changes in levels of soluble RAGEs in subjects receiving therapies such as statins, ACE inhibitors, or calcitrol [22] [23] [24] , this finding in HIV-infected subjects on PI therapy merits further investigation in larger numbers of subjects.
Our findings are in agreement with the only published report investigating a role for sRAGE in CVD in HIVinfected patients. In the study of Jeong and colleagues [34] , the authors suggested that sRAGE may have a protective effect against subclinical atherosclerosis in HIV in a Korean population. They noted that sRAGE levels inversely correlated with subclinical carotid atherosclerosis, as measured by carotid IMT and other metabolic variables in HIVinfected patients receiving ART. It is important to note, however, that no control (HIV-uninfected) group was included in that study and that the study was cross-sectional. In the present longitudinal study, our finding that lower baseline levels of esRAGE were associated with increased odds of CIMT progression in HIV-infected individuals suggests that lower levels of these soluble forms of esR-AGE may be a putative biomarker of mechanisms that initiate and/or perpetuate vascular inflammation.
While our study and that of Jeong conducted in HIVinfected subjects show that lower esRAGE and sRAGEs, respectively, were associated with higher baseline CIMT levels, there have been conflicting observations in the literature on the general relationship between levels of RAGEs and the presence or extent of cardiovascular disease. In some studies, lower versus higher levels of the sRAGEs appeared to be associated with higher disease burden or clinical status [20, 32] . In contrast to our study, many of these studies were of cross-sectional design. We predict that single time point analysis in individual subjects may not take into account the effects of various episodes of acute or sub-acute exacerbations of disease, particularly in the setting of superimposed long-standing chronic diseases such as HIVor diabetes. In addition, the majority of studies do not report the levels of both sRAGE and esRAGE.
A number of factors limit the generalizability of this study. Specifically, this cohort's median age was only 41 years and represents a population at lower risk for cardiovascular disease, which may have diminished our ability to differentiate cardiovascular disease in those with HIV infection to those without HIV. This study was not designed to investigate a role for sRAGE and/ or esRAGE in CVD among HIV-infected patients with detectable viremia, and the study participants differed by race and baseline triglyceride level from those in the original cohort. It is possible that cryopreservation affected the sRAGE and esRAGE results, but reassuring in this regard was that the levels we found were in the same range as those noted in other human studies [20] . In addition, there are limitations and challenges associated with use of any biomarker [35, 36] and surrogate endpoints [36] . However, because of the well-described role of RAGE in atherosclerosis, complications associated with diabetes, as well as other inflammatory disorders, and in view of the chronic inflammation and immune activation associated with HIV and prevalence of CVD beyond that predicted by the Framingham Risk Score, we propose that further investigation of a role for these molecules in the setting of HIV is indicated. Despite the fact that we did not identify an effect due to HIV in this cohort, we did observe that PI use may be associated with positive yearly rates of change of sRAGE and esRAGE and that HIV-infected subjects with lower baseline esRAGE displayed the most CIMT progression, consistent with some reports in other inflammatory conditions. Additional studies may further elucidate these observations and/or reveal whether RAGE contributes to or protects against accelerated atherosclerosis in a cohort of HIV-infected persons.
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